Y an et al in this issue of Angiology evaluate the impact of radial catheterization for coronary angiography and percutaneous coronary interventions (PCI). 1 They measured the radial artery diameter and intima-media thickness (IMT) before, 1 day and 1 month after transradial coronary procedures. The mean radial artery IMT increased from 0.25 + 0.12 mm before the procedure to 0.69 + 0.31 mm 1 day post procedure (P < .01) and decreased to 0.38 + 0.17 mm 1 month following the procedure (P < .05 compared with baseline). The mean radial artery diameter followed a similar pattern. 1 The incidence of radial artery stenosis and occlusion 1 day after transradial coronary procedures were 15.7% and 2.8%, respectively (P < .01 compared with baseline); 1 month after the procedures this decreased to 7.6% and 1.7%, respectively (P < .05 compared with baseline). 1 As mentioned by the authors, 1 the fluctuations in the radial artery diameter and IMT suggest that following catheterization an acute inflammatory reaction takes place, which induces local edema, intimal coarseness, and intima-media thickening. One month later, the radial artery IMT and diameter were still abnormal compared with before the procedure suggesting that recovery is not complete. These findings may have considerable implications in everyday clinical practice.
The changes induced to the radial artery catheterization may have consequences if this artery is used for radiocephalic arteriovenous fistula (AVF) in hemodialysis patients or as a conduit in individuals undergoing coronary artery bypass grafting (CABG). A study investigating the impact of increased radial artery IMT on the patency of radiocephalic AVF in hemodialysis patients showed that an increased preoperative radial artery IMT is associated with early failure of the AVF. 2 The mean radial artery IMT of the patients with a failed AVF was thicker compared with the patent AVF subgroup (486 + 130 vs 398 + 130 mm, respectively; P ¼ .004). 2 Similarly, a study comparing the 12-week patency rates of AVFs in patients with radial artery internal diameter <1.5 mm with patients with radial artery internal diameter >1.5 mm showed that a small preoperative radial artery diameter predicts early failure of the AVF. 3 While all patients with radial artery internal diameter >1.5 mm had a patent AVF at 12 weeks, 45% of those individuals with a radial artery diameter <1.5 mm showed thrombosis of the AVF. 3 These results were verified in another study. 4 Another study showed that microinflammation plays a role in the dysfunction of AVFs. 5 Therefore, careful artery selection may reduce the failure rates of AVFs. 4 A similar situation applies to patients undergoing CABG. A study comparing the injury to the radial artery in patients undergoing single or multiple transradial interventions showed that the lumen area and minimal lumen diameter in the latter group were This editorial was written independently; no company or institution supported the authors financially or by providing a professional writer. The authors have given talks, attended conferences, and participated in trials and advisory boards sponsored by various pharmaceutical companies. smaller than those in patients undergoing a single transradial intervention (P ¼ .032 and P ¼ .028, respectively), whereas the intima-media crosssectional area and IMT were greater (for both associations, P < .01). 6 Therefore, the damage associated with radial artery catheterization may be cumulative. It was concluded that it is necessary to ensure that the radial artery used as a conduit in CABG procedures has not been catheterized in the past. 6 A similar study supported that the radial arteries selected for CABG should undergo preoperative screening by Doppler ultrasonography to rule out intimal hyperplasia and/or occlusive lesions. 7 How these changes affect other arterial catheterizations (eg, carotid and femoral) is worth investigating. There is also a need to establish whether radial artery puncture for continuously monitoring the blood pressure (eg, in the intensive care unit) or to obtain a sample for blood gas analysis is also associated with similar damage.
Apart from avoiding using the catheterized radial artery, there may be alternative ways to reduce periprocedural radial artery damage. Besides a well-established role in hyperlipidemias/dyslipidemias, [8] [9] [10] statins also exert the so-called pleiotropic actions (eg, antiinflammatory and antithrombotic). [11] [12] [13] Current evidence implies that statin treatment is associated with improved outcomes in patients undergoing PCI and percutaneous renal artery revascularization procedures, endovascular abdominal aortic aneurysm repair, carotid angioplasty/stenting, and endovascular peripheral arterial interventions. 14 Recent data from an experimental rodent model also support the theory that statins suppress vascular intimal hyperplasia. 15 Statins also improve vascular endothelial function. 16 Furthemore, statin treatment reduces carotid IMT progression, as indicated in several studies. [17] [18] [19] A similar effect on the radial IMT should be expected. Therefore, routine statin treatment should be initiated in patients scheduled for percutaneous vascular interventions. Even if statins do not restore radial IMT, their use in patients scheduled for PCI is associated with other beneficial actions. For example, in the Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Acute Coronary Syndromes (ARMYDA-ACS) trial, pretreatment with atorvastatin (80 mg 12 hours prior to PCI with a further 40 mg preprocedure dose) conferred an 88% risk reduction of a 30-day major adverse cardiac events compared with placebo (P ¼ .004). 20 The recently published Naples study showed that the reduction in the incidence of periprocedural myocardial infarction in patients undergoing elective PCI may be achieved with even a single, high loading dose of statin. 21 Because radial artery catheterization is associated with a traumatic injury to the arterial endothelium, it is expected that this process is associated with an increase in circulating C-reactive protein (CRP) levels. C-reactive protein is a systemic marker of inflammation, atherosclerosis, and vascular disease. [22] [23] [24] In patients undergoing elective PCI, elevated postprocedural CRP levels are an independent determinant of minor myocardial injury. [25] [26] [27] Following lower extremity bypass operations, elevated CRP levels are associated with an increased risk of graft occlusion and postoperative events. [28] [29] [30] Statins reduce CRP levels. [31] [32] [33] C-reactive protein levels may be used to assess the effect of statins on arterial damage caused by catheterization.
In conclusion, radial artery catheterization for percutaneous vascular or coronary interventions is not always a benign procedure. It is potentially associated with short-as well as long-term effects, which jeopardize the integrity of the radial artery luminal wall and render it an inappropriate conduit for future CABG or AVF. The danger becomes greater with repetitive catheterizations where the injury may not recover. Future trials should assess whether patients scheduled to undergo a PCI or vascular procedure will benefit from preprocedural routine statin treatment to suppress vascular hyperplasia, improve arterial IMT, reduce CRP levels, and optimize endothelial function.
